Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: GlobeNewswire
Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./Dec. 2025Phase 2b data for rosnilimab in rheumatoid arthritis featured as late-breaking oral presentation at ACR Convergence 2025Phase 1b initiated in celiac disease for ANB033, a CD122 antagonist; top-line Phase 1b data anticipated in Q4 2026GSK announced strong commercial performance for Jemperli, growing 16% quarter-over-quarter to $303 million in Q3 2025 and $785 million YTD 2025Anaptys anticipates accruing a one-time $75 million commercial sales milestone in Q4 2025 from GSK once Jemperli achieves $1 billion in worldwide net sales$390 million in annualized Jemperli royalties payable to Anaptys at GSK’s peak sales guidance of $2.7 billion, which Anaptys expects to be achieved before 2031 SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- SA Quant ranks Goldman's small-cap stocks with largest short interest [Seeking Alpha]Seeking Alpha
- Anaptys Announces Participation in December Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Anaptys Announces Participation in December Investor ConferencesGlobeNewswire
- AnaptysBio (NASDAQ:ANAB) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $50.00 price target on the stock.MarketBeat
- AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at HC Wainwright from $52.00 to $51.00. They now have a "buy" rating on the stock.MarketBeat
ANAB
Earnings
- 11/4/25 - Beat
ANAB
Sec Filings
- 11/26/25 - Form 8-K
- 11/21/25 - Form 8-K
- 11/21/25 - Form 8-K
- ANAB's page on the SEC website